[go: up one dir, main page]

MX2009004113A - Composicion que comprende un antagonista del receptor de neuroquinina-1 y un inhibidor selectivo de la recaptacion de serotonina para el tratamiento de tinnitus y perdida auditiva. - Google Patents

Composicion que comprende un antagonista del receptor de neuroquinina-1 y un inhibidor selectivo de la recaptacion de serotonina para el tratamiento de tinnitus y perdida auditiva.

Info

Publication number
MX2009004113A
MX2009004113A MX2009004113A MX2009004113A MX2009004113A MX 2009004113 A MX2009004113 A MX 2009004113A MX 2009004113 A MX2009004113 A MX 2009004113A MX 2009004113 A MX2009004113 A MX 2009004113A MX 2009004113 A MX2009004113 A MX 2009004113A
Authority
MX
Mexico
Prior art keywords
novel use
tinnitus
hearing loss
ssri
medicament
Prior art date
Application number
MX2009004113A
Other languages
English (en)
Inventor
Tadataka Yamada
Soren Rahn Christensen
Pich Emilio Merlo
Emiliangelo Ratti
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2009004113A publication Critical patent/MX2009004113A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El uso de un antagonista del receptor de NK1 en combinación con un inhibidor selectivo de recaptación de serotonina (SSRI) en la fabricación de un medicamento para el tratamiento de tinnitus, pérdida auditiva, o tinnitus y pérdida auditiva.
MX2009004113A 2006-10-20 2007-10-18 Composicion que comprende un antagonista del receptor de neuroquinina-1 y un inhibidor selectivo de la recaptacion de serotonina para el tratamiento de tinnitus y perdida auditiva. MX2009004113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0621229.4A GB0621229D0 (en) 2006-10-20 2006-10-20 Novel use
PCT/EP2007/061144 WO2008046882A2 (en) 2006-10-20 2007-10-18 Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss

Publications (1)

Publication Number Publication Date
MX2009004113A true MX2009004113A (es) 2009-04-30

Family

ID=37545964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004113A MX2009004113A (es) 2006-10-20 2007-10-18 Composicion que comprende un antagonista del receptor de neuroquinina-1 y un inhibidor selectivo de la recaptacion de serotonina para el tratamiento de tinnitus y perdida auditiva.

Country Status (12)

Country Link
US (1) US20100317666A1 (es)
EP (1) EP2079470A2 (es)
JP (1) JP2010506884A (es)
KR (1) KR20090069340A (es)
CN (1) CN101568341A (es)
AU (1) AU2007312209A1 (es)
BR (1) BRPI0717600A2 (es)
CA (1) CA2666765A1 (es)
EA (1) EA200900575A1 (es)
GB (1) GB0621229D0 (es)
MX (1) MX2009004113A (es)
WO (1) WO2008046882A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
US9883300B2 (en) * 2015-02-23 2018-01-30 Oticon A/S Method and apparatus for controlling a hearing instrument to relieve tinitus, hyperacusis, and hearing loss
US11135397B2 (en) 2016-08-04 2021-10-05 Aureliym GmbH Two-dimensional acoustic CR neuromodulation using frequency and periodicity as control parameters
WO2023101418A1 (ko) * 2021-12-03 2023-06-08 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047514A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
AU2007312209A1 (en) 2008-04-24
EP2079470A2 (en) 2009-07-22
CA2666765A1 (en) 2008-04-24
WO2008046882A3 (en) 2009-01-29
WO2008046882A2 (en) 2008-04-24
US20100317666A1 (en) 2010-12-16
BRPI0717600A2 (pt) 2013-10-22
EA200900575A1 (ru) 2009-10-30
CN101568341A (zh) 2009-10-28
JP2010506884A (ja) 2010-03-04
GB0621229D0 (en) 2006-12-06
KR20090069340A (ko) 2009-06-30

Similar Documents

Publication Publication Date Title
SG170826A1 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
IN2012DN01869A (es)
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
SI1729753T1 (sl) Uporaba antagonistov NMDA receptorjev za zdravljenje tinitusa povzročenega s kohlearno eksitotoksičnostjo
TW200637522A (en) Skin treatment articles and methods
MX2008001652A (es) Copolimeros de poliamonio-polisiloxano.
MX2011007930A (es) Conjugados de insulina cristalina.
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
AU303032S (en) Seating unit without arms rests
SG170044A1 (en) Ocular allergy treatments
MX2010002733A (es) Terapia de intervalo para el tratamiento de tinnitus.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2009006812A (es) Moduladores del receptor c3a y metodos de uso de los mismos.
MX2012000572A (es) Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos.
WO2007137224A3 (en) Method of treatment
TW200509896A (en) Analeptic and drug combinations
MX2009004113A (es) Composicion que comprende un antagonista del receptor de neuroquinina-1 y un inhibidor selectivo de la recaptacion de serotonina para el tratamiento de tinnitus y perdida auditiva.
JO2730B1 (en) Medications for the treatment of endometriosis
WO2010120817A3 (en) Nanochanneled device and related methods
UA88655C2 (ru) S-миртазапин для лечения прилива крови
GEP20115158B (en) Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction
EA200801890A1 (ru) Средство для лечения шума в ушах
PT1713438E (pt) Sabonete medicinal
MY166063A (en) Intravenous antiviral treatments

Legal Events

Date Code Title Description
HH Correction or change in general